Maen Hussein, MD
Medical Oncology · Tavares, FLNPI 1356332506
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (55.7%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 14.0%. Among medical oncology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,258 payments — averaging $136.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$24K
- E.r. Squibb & Sons, L.L.C.$19K
- Ipsen Biopharmaceuticals, Inc$14K
- AstraZeneca$13K
- Pfizer$10K
- Boehringer Ingelheim International GmbH$8K
- plus $81K from 54 others
Across 1,696 payments — averaging $10,733 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$8.9M
- Genentech, Inc.$2M
- AstraZeneca$1.7M
- Aadi Bioscience, Inc.$1.1M
- E.r. Squibb & Sons, L.L.C.$1M
- Boehringer Ingelheim International GmbH$668K
- plus $2.8M from 14 others
What the payments were for
- Consulting fees$95,88656%
- Speaking & faculty fees$45,66127%
- Travel & lodging$3,8412%
- Food & beverage$25,28315%
- Education$7170%
- Other$6650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$172,053 in reported general payments places this provider in the 95th percentile of 507 medical oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 154 | $2,539,656 |
| ImbruvicaIbrutinib | 92 | $991,536 |
| IbrancePalbociclib | 59 | $945,343 |
| BrukinsaZanubrutinib | 57 | $830,051 |
| PomalystPomalidomide | 32 | $728,015 |
| JakafiRuxolitinib Phosphate | 49 | $694,041 |
| TagrissoOsimertinib Mesylate | 40 | $650,921 |
| CalquenceAcalabrutinib Maleate | 37 | $402,983 |
| LynparzaOlaparib | 27 | $390,845 |
| WeliregBelzutifan | 11 | $326,547 |
| CabometyxCabozantinib S-Malate | 12 | $297,923 |
| LenvimaLenvatinib Mesylate | 12 | $282,931 |
| VerzenioAbemaciclib | 14 | $212,082 |
| VenclextaVenetoclax | 31 | $180,493 |
| InqoviDecitabine/Cedazuridine | 20 | $167,489 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $1,396 | $2,539,656154 claims |
| AstraZenecaTagrisso, Calquence, Lynparza | $13,175 | $1,444,749104 claims |
| PfizerIbrance, Eliquis | $10,346 | $1,079,681192 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $646 | $991,53692 claims |
| Beigene USA, Inc.Brukinsa | $2,985 | $830,05157 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $19,344 | $728,01532 claims |
| Incyte CorporationJakafi | $2,756 | $694,04149 claims |
| MerckWelireg | $1,173 | $326,54711 claims |
| Exelixis Inc.Cabometyx | $1,611 | $297,92312 claims |
| Eisai Inc.Lenvima | $743 | $282,93112 claims |
| AbbVieVenclexta, Creon | $4,737 | $213,36746 claims |
| Lilly USA, LLCVerzenio | $3,987 | $212,08214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 507 medical oncology providers in Florida.
Other medical oncology in Tavares
- Neil LoveMiami$5.6M
- Mahdi TahaBoca Raton$1.7M
- Raji ShameemOrlando$1.3M
- Mohammad JahanzebBoca Raton$1.3M
- Michel VelezOrlando$927K
- Yuanbin ChenOrlando$810K
- Reshma MahtaniPlantation$608K
- Rebecca MorooseOrlando$543K
- Yasser KhaledOrlando$444K
- Judah FriedmanPalm Beach Gardens$416K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.